Abstracts tagged "patient-reported outcome measures and quality of life"

Abstract Number: 1656 • 2019 ACR/ARP Annual Meeting
Health-Related Quality of Life in Patients with Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-ILD): Impact of Lung Function on Patient-Reported Outcomes in a Randomized Phase III Trial
Michael Kreuter ¹, Anna Maria Hoffmann-Vold ², Marco Matucci-Cerinic ³, Lesley Saketkoo ⁴, Kristin Highland⁵, Hilary Wilson ⁶, Margarida Alves ⁷, Nils Schoof ⁶ and Toby Maher ⁸, ¹Center for Interstitial and Rare Lung Diseases, Pneumology, Thoraxklinik, University of Heidelberg, Member of the German Center for Lung Research, Germany, Germany, Germany, ²Department of Rheumatology, Oslo University Hospital, Oslo, Norway, Oslo, Norway, ³University of Florence, Department of Medicine, Florence, Italy, Florence, Italy, ⁴New Orleans Scleroderma and Sarcoidosis Patient Care and Research Center, New Orleans; Tulane University School of Medicine, University Medical Center – Comprehensive Pulmonary Hypertension Center, USA, New Orleans, ⁵Cleveland Clinic, Cleveland, Ohio, USA, Cleveland, OH, ⁶Boehringer Ingelheim International GmbH, Ingelheim am Rhein, Germany, ⁷Boehringer Ingelheim International GmbH, Ingelheim am Rhein, Germany, Ingelheim am Rhein, Germany, ⁸National Heart and Lung Institute, Imperial College London, UK and National Institute for Health Research Clinical Research Facility, Royal Brompton Hospital, London, UK, London, United Kingdom
Background/Purpose: SSc-ILD is a major cause of morbidity and mortality in patients with systemic sclerosis. A subset of patients with SSc-ILD show a decline in…
Abstract Number: 474 • 2018 ACR/ARHP Annual Meeting
Lupus Impact Tracker (LIT) As a New Tool in Assessing Patient Reported Outcome in Pediatric Lupus
Suhas Ganguli¹, Joyce Hui-Yuen¹, Meenakshi Jolly^2,3, Jane Cerise⁴ and B. Anne Eberhard⁵, ¹Pediatric Rheumatology, Cohen Children's Medical Center, Lake Success, NY, ²Rush University Medical Center, Chicago, IL, ³Rheumatology, Rush University Medical Center, Chicago, IL, ⁴Biostatistics, The Feinstein Institute for Medical Research, Manhasset, NY, ⁵Pediatric Rheumatology, Cohen Children's Medical Center, New Hyde Park, NY
Background/Purpose: Patient Reported Outcome (PRO) measures for Quality of Life (QoL) in patients with lupus are useful supplements to the physician-derived indices of disease activity…
Abstract Number: 870 • 2018 ACR/ARHP Annual Meeting
Patient-Reported Burden of Gout in 2017 from the United States
Puja P. Khanna¹, Douglas C.A. Taylor², An-Chen Fu² and Robert Morlock³, ¹University of Michigan, Ann Arbor, MI, ²Ironwood Pharmaceuticals, Inc., Cambridge, MA, ³YourCareChoice, Ann Arbor, MI
Background/Purpose: Gout is reported to impact 3.9% of the US adult population (Zhu. Arthritis Rheum 2011;63:3136-41). Treatment encompasses controlling acute attacks (flares) and, dependent on…
Abstract Number: 1384 • 2018 ACR/ARHP Annual Meeting
Health-Related Quality of Life in Patients with Ankylosing Spondylitis in the United States
W. Benjamin Nowell¹, Regan Reynolds¹, Kelly Gavigan¹, Shilpa Venkatachalam¹, Marie de la Cruz², Emuella Flood², Ethan Schwartz², Beverly Romero², Yujin Park³ and Alexis Ogdie⁴, ¹Global Healthy Living Foundation, Upper Nyack, NY, ²ICON, Gaithersburg, MD, ³Novartis Pharmaceuticals Corporation, East Hanover, NJ, ⁴Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA
Background/Purpose: Ankylosing spondylitis (AS) is a chronic, systemic, inflammatory disease that affects primarily the sacroiliac joints and spine and can cause irreversible damage. Measuring disease…
Abstract Number: 1402 • 2018 ACR/ARHP Annual Meeting
The Relationship of Pain, Fatigue and Emotional Distress with Quality of Life in Juvenile Myositis
Kyle J. Fahey¹, Elizabeth L. Gray², Rowland W. Chang³, David Cella⁴, Lauren M. Pachman⁵ and Kaveh Ardalan⁶, ¹Pediatrics, Northwestern University Feinberg School of Medicine, Chicago, IL, ²Preventive Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL, ³Preventive Medicine, Medicine, and Physical Medicine & Rehabilitation, Northwestern University Feinberg School of Medicine, Chicago, IL, ⁴Departments of Medical Social Sciences, Neurology, Pediatrics, Preventive Medicine, and Psychiatry and Behavioral Sciences,, Northwestern University Feinberg School of Medicine, Chicago, IL, ⁵Cure JM Program of Excellence in Juvenile Myositis Research, Stanley Manne Children’s Research Institute, affiliated with Ann & Robert H. Lurie Children’s Hospital of Chicago, Chicago, IL, ⁶Departments of Pediatrics and Medical Social Sciences, Division of Rheumatology, Northwestern University Feinberg School of Medicine/Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, IL
Background/Purpose: Juvenile Myositis (JM) is an autoimmune disease that negatively impacts quality of life (QoL) outcomes via muscle weakness and vasculopathic rashes. The relative contribution…
Abstract Number: 121 • 2013 ACR/ARHP Annual Meeting
Comparative Burden Of Chronic Widespread Pain and Fibromyalgia In The US Population
Caroline Schaefer¹, Rachael Mann², Elizabeth T. Masters³, Joseph C. Cappelleri⁴, Shoshana Daniel⁵, Gergana Zlateva³, Heather McElroy⁶, Arthi B. Chandran³, Edgar H. Adams¹, Annlouise R. Assaf⁴, Michael McNett⁷, Philip Mease⁸, Stuart L. Silverman⁹ and Roland Staud¹⁰, ¹Covance Market Access Services Inc., Gaithersburg, MD, ²Covance Market Access Services Inc., San Diego, CA, ³Pfizer Inc., New York, NY, ⁴Pfizer Inc., Groton, CT, ⁵Covance Market Access Services Inc., Conshohocken, PA, ⁶Covance Market Access Services, Sydney, Australia, ⁷Aurora Pain Program, Milwaukee, WI, ⁸Director, Rheumatology Research, Swedish Medical Center, Seattle, WA, ⁹Cedars-Sinai Medical Center, UCLA Center of Excellence, Los Angeles, CA, ¹⁰Dept Med/Rheum/Clin Immun Div, University of Florida, Gainesville, FL
Background/Purpose: Few data exist on the comparative burden of chronic widespread pain (CWP) and fibromyalgia (FM) in the general population. Methods: 8,382 nationally representative participants…
Abstract Number: 479 • 2013 ACR/ARHP Annual Meeting
Attainment Of Remission, Functional, and Quality Of Life Improvements With Golimumab Treatment In Rheumatoid Arthritis Are Associated With Patient Expectations
B Dasgupta¹, B Combe², I Louw³, J Wollenhaupt⁴, C Zerbini⁵, A Beaulieu⁶, H Schulze-Koops⁷, P Durez⁸, V Wolff⁹, R Yao¹⁰, HH Weng¹⁰, M Govoni¹¹ and N Vastesaeger¹², ¹Southend University Hospital, Westcliff-on-Sea, United Kingdom, ²Hôpital Lapeyronie, Montpellier, France, ³Panorama Medical Centre, Cape Town, South Africa, ⁴Schön-Klinik, Hamburg, Germany, ⁵Hospital Heliópolis, Serviço de Reumatologia, São Paulo, Brazil, ⁶Centre de Rhumatologie, St-Louis, QC, Canada, ⁷University of Munich, Munich, Germany, ⁸Université Catholique de Louvain and Cliniques Universitaires Saint-Luc, Brussels, Belgium, ⁹Hospital del Salvador, Santiago, Chile, ¹⁰Merck & Co., Inc., Whitehouse Station, NJ, ¹¹MSD Italy, Rome, Italy, ¹²Merck Sharp & Dohme, Brussels, Belgium
Background/Purpose: Golimumab (GLM) and other tumor necrosis factor antagonists are used as add-on therapy for patients with rheumatoid arthritis (RA) who have not responded to…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].